CD8A and neoplasm: However, the poor CD8+ T-cell response is mainly due to lack of neoantigens for T-cell recognition, incomplete antigen presentation, and loss of major histocompatibility complex (MHC) class I. A sustained immunosuppressive tumor microenvironment (TME) also contributes to immunotherapy resistance.